Reviewing PainReform (NASDAQ:PRFX) and BioNxt Solutions (OTCMKTS:BNXTF)

PainReform (NASDAQ:PRFX) and BioNxt Solutions (OTCMKTS:BNXTF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.

Risk and Volatility

PainReform has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, BioNxt Solutions has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for PainReform and BioNxt Solutions, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1	0	0	0	1.00
BioNxt Solutions	0	0	0	0	0.00

Insider and Institutional Ownership

37.3% of PainReform shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares PainReform and BioNxt Solutions”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20,000.00	71.78	-$5.02 million	($736.66)	0.00
BioNxt Solutions	$20,000.00	1,531.08	-$5.43 million	($0.05)	-5.00

BioNxt Solutions is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PainReform and BioNxt Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
BioNxt Solutions	N/A	N/A	-879.46%

Summary

PainReform beats BioNxt Solutions on 7 of the 9 factors compared between the two stocks.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

About BioNxt Solutions

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.